| | | |   | | | | By Allison DeAngelis and Kate Sheridan Adobe Data show that, while more established VC firms were able to capitalize on the biotech boom, Silicon Valley firms grew at far higher rates. Read More | | By Adam Feuerstein Adobe The company continues to enroll and treat additional participants, with updated study results expected next year. Read More | | By Adam Feuerstein and Damian Garde Sebastien Bozon/AFP via Getty Images The failure of the drug, called gantenerumab, is a setback for Roche and its efforts to develop a treatment for Alzheimer's Read More | | Sponsored Insight by The University of Texas MD Anderson Cancer Center A drug development engine housed within an academic cancer center MD Anderson researchers are committed to answering the most pressing unmet needs in oncology and delivering the next wave of cancer breakthroughs. With industry expertise and seamless collaboration across the institution, MD Anderson's Therapeutics Discovery division is building upon these discoveries to advance innovative therapies to patients quickly, safely and effectively. This unique drug development engine is seeking exceptional scientists for a variety of positions. Learn more about their work and available opportunities here. | | By Tara Bannow Julia Rendleman/Getty Images for Eventive Marketing Insurers mastered profiting from value-based care under MA. With its $2.7 billion VillageMD acquisition, Cigna hopes to follow that route. Read More | | By Jonathan Wosen Courtesy UAW Academic workers at 10 University of California campuses launched a strike, decrying low wages that leave many struggling to afford rent. Read More | |
No comments